Integral to the management of type 2 diabetes is ensuring that the attendant blood lipid abnormalities are optimally treated.
Guidelines abound setting out specific targets for these lipid sub-fractions, yet clinical trials and real-world data consistently document the failure to achieve these numeric endpoints. Because cardiovascular conditions such as atherosclerotic heart disease and stroke remain the leading cause of death in people with diabetes, reversing this apparent clinical inertia is mandatory. Decades worth of published trials confirm the fundamental place of statins in the treatment paradigm. What then is the role of non-statin treatments?
